Qube Research & Technologies LTD Catalyst Pharmaceuticals, Inc. Transaction History
Qube Research & Technologies LTD
- $93.8 Billion
- Q2 2025
A detailed history of Qube Research & Technologies LTD transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 1,014,410 shares of CPRX stock, worth $21.3 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,014,410
Previous 760,296
33.42%
Holding current value
$21.3 Million
Previous $18.4 Million
19.39%
% of portfolio
0.02%
Previous 0.02%
Shares
15 transactions
Others Institutions Holding CPRX
# of Institutions
386Shares Held
103MCall Options Held
0Put Options Held
277K-
Black Rock Inc. New York, NY18.7MShares$393 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$184 Million0.0% of portfolio
-
State Street Corp Boston, MA5.48MShares$115 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.25MShares$68.3 Million0.1% of portfolio
-
Morgan Stanley New York, NY3.18MShares$66.9 Million0.0% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.16B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...